Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1830 in Pemphigus
NCT03075904Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of orilanolimab in pemphigus vulgaris (PV), pemphigus foliaceus (PF), sponsored by Alexion Pharmaceuticals. Started Jul 2017; status: terminated.
02
Drugs
orilanolimab
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT03075904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075904.